Idelalisib, a selective oral inhibitor of PI3Kδ, was approved by the FDA and EMA as monotherapy for patients with advanced follicular lymphoma (FL) based on positive efficacy and safety results from the registration phase 2 trial in patients with indolent non-Hodgkin lymphoma (iNHL) refractory to 2 prior regimens (NCT01282424; 101-09). Phase 3 studies of idelalisib in earlier lines of treatment for iNHL were terminated prematurely due to an increased risk of death and higher incidence of serious adverse events (AEs) associated with idelalisib. Herein, we present the preplanned interim results as of June 8, 2020, of the safety of idelalisib monotherapy in patients with refractory FL treated in the EU from one of the largest noninterventional trials of idelalisib.
Safety Profile of Idelalisib in Patients with Refractory Follicular Lymphoma: Interim Analysis of a Noninterventional Study / Salles, Gilles; Wu, Ka Lung; Kovalchuk, Sofya; Mercadal, Santiago; Chiarenza, Annalisa; Pettengell, Ruth; Vandenberghe, Elisabeth; Corradini, Paolo; Carvalho, Susana; De Belder, Christophe; Shah Gupta, Rikisha; van Troostenburg, Anna; Rajakumaraswamy, Nishanthan; Ramroth, Heribert. - In: BLOOD. - ISSN 0006-4971. - ELETTRONICO. - 136:(2020), pp. 48-50. [10.1182/blood-2020-137607]
Safety Profile of Idelalisib in Patients with Refractory Follicular Lymphoma: Interim Analysis of a Noninterventional Study
Kovalchuk, Sofya
;Corradini, Paolo;
2020
Abstract
Idelalisib, a selective oral inhibitor of PI3Kδ, was approved by the FDA and EMA as monotherapy for patients with advanced follicular lymphoma (FL) based on positive efficacy and safety results from the registration phase 2 trial in patients with indolent non-Hodgkin lymphoma (iNHL) refractory to 2 prior regimens (NCT01282424; 101-09). Phase 3 studies of idelalisib in earlier lines of treatment for iNHL were terminated prematurely due to an increased risk of death and higher incidence of serious adverse events (AEs) associated with idelalisib. Herein, we present the preplanned interim results as of June 8, 2020, of the safety of idelalisib monotherapy in patients with refractory FL treated in the EU from one of the largest noninterventional trials of idelalisib.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.